Hot High Tech Stocks To Watch Right Now

I'm going to attempt something a little odd today, Fools. Even though�Apple (NASDAQ: AAPL  ) makes up 6.2% of my real-life holdings, and I�recently considered �buying shares of Apple stock, I'm going to be giving you two reasons to consider selling shares of the company today.

Why am I doing this?

Recently, Nobel Prize winner Daniel Kahneman visited Fool headquarters in Virginia. While visiting, he talked about how a number of different biases can lead us to believe we can predict the future with relative certainty. In reality, he argued, we're just deluding ourselves.

It got me to thinking about how I don't write enough about the�risks�of owning the stocks I own. So, although I don't plan on selling my Apple stock anytime soon, I think it's healthy for me to practice and model this behavior.

Hot High Tech Stocks To Watch Right Now: NewLead Holdings Ltd.(NEWL)

NewLead Holdings Ltd. operates as an international shipping company that owns and operates product tankers and dry bulk carriers. It operates in two segments, Wet Operations and Dry Operations. The Wet Operations segment transports various refined petroleum products simultaneously in segregated coated cargo tanks that include gasoline, jet fuel, kerosene, naphtha, and gas oil. The Dry Operations segment involves in transporting and handling bulk cargoes through ownership, operation, and trading of vessels. As of August 2, 2011, the company operated a fleet of 6 double-hull product tankers and 16 dry bulk vessels. The company was formerly known as Aries Maritime Transport Limited and changed its name to NewLead Holdings Ltd. in December 2009. NewLead Holdings Ltd. was incorporated in 2005 and is based in Athens, Greece.

Advisors' Opinion:

• [By Monica Gerson]

  NewLead Holdings (NASDAQ: NEWL) shares dipped 6.56% to touch a new 52-week low of $0.08 after the company completed the acquisition of titles in the Viking Mine located in Kentucky, USA.

Hot High Tech Stocks To Watch Right Now: Biosante Pharmaceuticals Inc.(BPAX)

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of various products for female sexual health and oncology. It provides LibiGel, a transdermal testosterone gel that is in Phase III clinical development for the treatment of female sexual dysfunction; and male testosterone gel for the treatment of hypogonadism in men, which is licensed to Teva Pharmaceuticals USA, Inc. The company also offers various cancer vaccines, which are in Phase I and Phase II clinical trials for the treatment of melanoma, leukemia, pancreatic, breast, and prostate cancer; The Pill-Plus, which is in Phase II clinical trials is a combination of estrogens, progestogens, and androgens to prevent testosterone deficiency; and Elestrin, a food and drug administration approved product for the treatment of hot flashes associated with menopause. BioSante Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Lincolnshire, Illinois.

Hot Gold Stocks To Watch Right Now: Hmv Group(HMV.L)

HMV Group plc operates as a specialist retailer of filmed entertainment, games, music, and portable digital technology products under the HMV and Fopp brands. It operates entertainment stores and Web sites in the United Kingdom, Ireland, Hong Kong, and Singapore. In addition, the company owns and operates live music venues and summer music festivals, as well as involves in related ticketing activities. It operates approximately 273 retail stores, 14 entertainment venues, and 6 festivals. The company was founded in 1921 and is headquartered in Maidenhead, the United Kingdom.

Hot High Tech Stocks To Watch Right Now: Dendreon Corporation(DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The company offers active cellular immunotherapy and small molecule product candidates to treat various cancers. Its product candidates comprise Provenge (sipuleucel-T), an active cellular immunotherapy for the treatment of metastatic, castrate-resistant prostate cancer; DN24-02, an investigational active immunotherapy for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and TRPM8, a small molecule agonist to transient receptor potential ion channel, for multiple cancers. The company also has a range of products in preclinical studies, which include Carcinoembryonic antigen for the treatment of lung, colon, and breast cancer; and Carbonic AnhydraseIX for the treatment of kidney cancer. Dendreon Corporation was founded in 1992 and is headquartered in S eattle, Washington.

Advisors' Opinion:

• [By Jon C. Ogg]

  Dendreon Corp. (NASDAQ: DNDN) is hitting 52-week lows as Deutsche Bank has downgraded the maker of Provenge to Sell from Hold. Shares are down 5% at $3.03, against a prior 52-week range of $3.10 to $7.22.

• [By Bryan Murphy]

  There's no doubt about it - the "in" thing to do with Dendreon Corporation (NASDAQ:DNDN) lately has been to bash it. The company's one and only drug, Provenge, failed to meet its sales estimates last quarter. And worse, DNDN was forced to announce 2013's top line wouldn't be as strong as first expected. Between that lowered guidance and growing fears that Provenge may not be nearly as marketable as first assumed, the stock plunged 26% on Friday, and has since widened that loss to 30%.

• [By Johanna Bennett]

  Once, one of the hottest biotech stocks around, Dendreon (DNDN) has become a cautionary tale, warning investors what can happen when a cutting-edge�drug turns into a dud.

  Now at less than $3 a share, the stock had traded as high as $54 in 2010 as excitement buzzed over the�experimental prostate cancer vaccine Provenge. Initially, Wall Street expected peak sales of $3 billion to $4 billion. But insurers balked at the�hefty price tag for Provenge, and now, three years after it�won FDA approval, analysts see annual sales at roughly $300 million.

  Disappointing sales are just one reason Deutsche Bank has joined the�bearish�voices surrounding this drug maker.�Today, analyst Robyn Karnauskas downgraded Dendreon�to a Sell and cut the�price target to $1, warning that even if the company�can significantly reduce�costs and drastically restructures, its�spending may still outpace revenue growth in the short-term. Karnauskas believes Dendreon may have to refinance its debt, negatively impacting shareholders.

  Earlier this month, the company�posted a bigger-than-expected second-quarter loss as Provenge sales fell compared to last year. A restructuring plan was�unveiled in late July, though�analysts say it isn’t enough without revenue growth.�Today, Deutsche Bank’s Karnauskas writes:�

  …By our math, even with $165M in cost cuts, the co will have to grow current sales from $300M to $525M over next 7 years to support current share price. 2Q13 sales were $73M and DTC campaign does not seem to have a lot of effect to offset impact from competition so that the company could reach profitability in 4Q13. While they note that they plan to cut costs, we are concerned it may be too late. Revenue growth is not occurring quick enough; we note 1Q13 yoy growth was guided and in 2Q13 they noted this was unlikely to occur going fwd. The co�� inability to guide growth & provide visibility makes it difficult for us to see sales a

Hot High Tech Stocks To Watch Right Now: Britannica Resources Corp (BRR.V)

Britannica Resources Corp., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties in Canada. It holds interests in the Chassignol, Deltador, Bluebird, and Kino projects located in the Abitibi Gold District of Quebec. The company is based in Toronto, Canada.